DSM and Svelte Medical Systems have signed a license and supply contract, which offers the right for Svelte to employ the DSM’s drug carrier based on bioerodible amino acid for the design of non-inflammatory, non-thrombogenic drug-eluting stent system.
The biocompatible drug carrier of DSM has altered the approach. By means of an exclusive enzyme-mediated bioerosion, active compounds are provided to the body. According to the joint development and collaboration agreement, DSM and Svelte have been working from November 2010 and this contract implementation has confirmed the capacity of drug delivery technology and new properties of polyesteramide (PEA) biomaterials of DSM.
The CEO and President of Svelte Medical Systems, Mark Pomeranz stated that the balloon expandable coronary stent technology has been offered by the coronary stent platform in the market. Partnership with DSM can extend the platform for technology and release the expected second generation product. Drug delivery technology from DSM combined with the sirolimus drug has the possibility for advancing patient safety and reduces the requirement for dual anti-platelet therapy.
DSM’s Global Business Director for Drug Delivery, Donato DiBiase has commented that the bioerodible drug carrier is perfect for offering a series of active pharmaceutical agents, which contain immunosuppressants, protective agents for blood clotting, and several other drugs during degradation in a natural, biocompatible, controlled, and non-toxic way. This drug carrier uses an approach similar to the delivery of active compounds from stent systems.
DSM Biomedical’s President, Christophe Dardel has stated that the potential of DSM to generate drug carriers that provides new functions for the efficiency of medical devices continues to distinguish the company in the biomaterials area. DSM is excited to work with Svelte because of the interventional cardiology technology platform extension.
Source: http://www.dsm.com/